PlainRecalls
ModerateClass IICompleted

FDA Drug recall · Reported April 24, 2013

Levoxyl (levothyroxine sodium) tablets, USP 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles ( NDC 60793-860-10 ) Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620.

Chemical contamination: emission of strong odor after package was opened.

Recall #
D-261-2013
Affected scope
14464 bottles
Initiated
March 28, 2013
Compiled from official public sources by the editorial team.
Verify with FDA Drug →
View my saved recalls

Pfizer Inc. recalled Levoxyl (levothyroxine sodium) tablets, USP 200 mcg, packaged in a) 100-count bottles (ND… - a moderate-severity action.

Levoxyl (levothyroxine sodium) tablets, USP 200 mcg, packaged in a) 100-count bottles (ND… was recalled by Pfizer Inc. in April 24, 2013. Reason: Chemical contamination: emission of strong odor after package was opened.. Check the official notice for the remedy. Verify recall #D-261-2013 with the FDA Drug before acting.

The recall

Pfizer Inc. issued this moderate-severity FDA Drug recall-Chemical contamination: emission of strong odor after package was opened..

Moderate
severity level
Class II
classification
April 24, 2013
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-261-2013 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This FDA Drug action (record #D-261-2013) was formally reported on April 24, 2013, with the manufacturer initiating the action on March 28, 2013. It is classified under Moderate severity (Class II), with a current status of Completed. Pfizer Inc. is listed as the recalling firm, operating out of New York, NY. Federal records list the affected scope as 14464 bottles.

The documented reason for this recall is: Chemical contamination: emission of strong odor after package was opened. Distribution data in the federal record shows the product reached: Nationwide and PR. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Drugs & Medications recalls over time

Where this recall sits in its category - 14,287 drugs & medications recalls on record

-50005001,0001,5002,000 2006201220152018202120242026 263
Severity2487872426High severity (most serious)Moderate severityLow severity
Where this recall sits in the database

Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Severity

Moderate

Affected scope

14464 bottles

Related Recalls

6

5 from same agency

Product description

Levoxyl (levothyroxine sodium) tablets, USP 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles ( NDC 60793-860-10 ) Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620.

Reason for recall

Chemical contamination: emission of strong odor after package was opened.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute Value
Agency U.S. Food and Drug Administration
Severity class Moderate (Class II)
Status Completed
Recall number D-261-2013
Date reported April 24, 2013
Date initiated March 28, 2013
Recalling firm Pfizer Inc.
Firm location New York, NY
Affected scope 14464 bottles
Distribution Nationwide and PR

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

  • Check the recall number (D-261-2013) and product description against the item you own. Search the archive
  • Confirm the current status with FDA Drug before acting, recall details can be updated.
  • Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled?
Levoxyl (levothyroxine sodium) tablets, USP 200 mcg, packaged in a) 100-count bottles (NDC 60793-860-01) and b) 1000-count bottles ( NDC 60793-860-10 ) Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620.. Recalled by Pfizer Inc.. Units affected: 14464 bottles.
Why was this product recalled?
Chemical contamination: emission of strong odor after package was opened.
Which agency issued this recall?
This recall was issued by the FDA Drug on April 24, 2013. Severity: Moderate. Recall number: D-261-2013.
Where was the recalled product distributed?
Distribution: Nationwide and PR.
How do I check if my product is affected by a recall?
Check the product description and recall number (D-261-2013) against your product. Visit the official FDA Drug website for the most current information. You can also use our Recall Checker tool to search by product name or brand.
Should I stop using a recalled medication or medical device?
Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nearby Recalls in This Category

Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.

Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →

Browse all Drugs & Medications recalls →

Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported April 24, 2013. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.